128.52

3.59% -4.78

After Hours: 129.20 0.68 +0.53%

Transmedics Group Inc (TMDX)

Overview News Price History Option Chain Financials Why TMDX Down? Discussions Forecast

Transmedics Group Inc stock is traded at $128.52, with a volume of 506.94K. It is down -3.59% in the last 24 hours and down -4.56% over the past month. TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Previous Close:

$133.30

Open:

$133

24h Volume:

506.94K

Relative Volume:

0.68

Market Cap:

$4.39B

Revenue:

$531.29M

Net Income/Loss:

$71.66M

P/E Ratio:

66.46

EPS:

1.9338

Net Cash Flow:

$17.35M

1W Performance:

-0.83%

1M Performance:

-4.56%

6M Performance:

-1.99%

1Y Performance:

+84.87%

1-Day Range:

$127.71

$134.52

1-Week Range:

$127.71

$140.72

52-Week Range:

$62.07

$156.00

Transmedics Group Inc Stock (TMDX) Company Profile

Name

Transmedics Group Inc

Sector

Healthcare (1112)

Industry

Medical Devices (141)

Phone

(978) 552-0900

Address

200 MINUTEMAN ROAD, ANDOVER, MA

Employee

728

Twitter

@transmedics

Next Earnings Date

2024-10-28

Latest SEC Filings

TMDX's Discussions on Twitter

Compare TMDX vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TMDX Transmedics Group Inc	128.52	4.56B	531.29M	71.66M	17.35M	1.9338
ABT Abbott Laboratories	111.47	197.52B	44.33B	6.48B	6.92B	3.7033
SYK Stryker Corp	365.85	139.09B	25.12B	3.25B	4.28B	8.4018
MDT Medtronic Plc	100.88	129.59B	34.76B	4.79B	5.21B	3.7017
BSX Boston Scientific Corp	74.12	108.96B	20.08B	2.89B	3.82B	1.9391
EW Edwards Lifesciences Corp	76.44	46.04B	6.07B	1.06B	799.60M	1.8527

Transmedics Group Inc Stock (TMDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-23-25	Upgrade	Needham	Hold → Buy
Oct-13-25	Initiated	Jefferies	Buy
Sep-16-25	Initiated	Evercore ISI	Outperform
Sep-04-25	Initiated	Stifel	Hold
Dec-17-24	Downgrade	JP Morgan	Overweight → Neutral
Nov-22-24	Downgrade	Needham	Buy → Hold
Oct-29-24	Reiterated	Needham	Buy
Oct-29-24	Reiterated	Oppenheimer	Outperform
Sep-24-24	Initiated	Robert W. Baird	Outperform
Aug-21-24	Initiated	Needham	Buy
Jun-06-24	Initiated	Cantor Fitzgerald	Overweight
Jun-04-24	Initiated	Stephens	Overweight
Mar-28-24	Initiated	Piper Sandler	Overweight
Jul-19-23	Initiated	Robert W. Baird	Outperform
Aug-02-22	Upgrade	JP Morgan	Neutral → Overweight
Oct-08-20	Downgrade	JP Morgan	Overweight → Neutral
Apr-07-20	Initiated	Oppenheimer	Outperform
May-28-19	Initiated	Canaccord Genuity	Buy
May-28-19	Initiated	Cowen	Outperform
May-28-19	Initiated	JP Morgan	Overweight
May-28-19	Initiated	Morgan Stanley	Equal-Weight

View All

Transmedics Group Inc Stock (TMDX) Latest News

Feb 12, 2026

Is Now An Opportune Moment To Examine TransMedics Group, Inc. (NASDAQ:TMDX)? - Yahoo Finance

Feb 12, 2026

How Do Investors Really Feel About TransMedics Group Inc? - Benzinga

Feb 12, 2026

Big Money Moves: What makes TransMedics Group Inc stock attractive todayMarket Rally & Fast Exit and Entry Trade Guides - baoquankhu1.vn

Feb 12, 2026

Feb 11, 2026

What Is TransMedics Group, Inc.'s (NASDAQ:TMDX) Share Price Doing? - 富途牛牛

Feb 11, 2026

Feb 10, 2026

TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - marketscreener.com

Feb 10, 2026

TransMedics receives full FDA approval for heart transplant trial By Investing.com - Investing.com Nigeria

Feb 10, 2026

Feb 09, 2026

TransMedics (TMDX) Secures FDA Approval for Advanced Heart Device Trial - GuruFocus

Feb 09, 2026

TransMedics receives full and unconditional FDA IDE approval for next-generation OCS Heart Enhance trial - marketscreener.com

Feb 09, 2026

TransMedics receives full FDA approval for heart transplant trial - Investing.com

Feb 09, 2026

TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial - PR Newswire

Feb 09, 2026

New York State Common Retirement Fund Sells 134,406 Shares of TransMedics Group, Inc. $TMDX - MarketBeat

Feb 09, 2026

Feb 08, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Reach Out - ACCESS Newswire

Feb 08, 2026

Seaport Research to Host Virtual Meeting Focusing on TMDX - GuruFocus

Feb 08, 2026

Feb 07, 2026

Renaissance Group LLC Acquires Shares of 76,078 TransMedics Group, Inc. $TMDX - MarketBeat

Feb 07, 2026

Principal Financial Group Inc. Purchases 53,995 Shares of TransMedics Group, Inc. $TMDX - MarketBeat

Feb 07, 2026

TD Cowen Sticks to Its Buy Rating for TransMedics Group (TMDX) - The Globe and Mail

Feb 07, 2026

Feb 06, 2026

TransMedics Group Names New Commercial Leader - The Globe and Mail

Feb 06, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Stockholders to Connect - ACCESS Newswire

Feb 06, 2026

Feb 04, 2026

Commit To Buy TransMedics Group At $80, Earn 16.2% Using Options - Nasdaq

Feb 04, 2026

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), UnitedHealth (UNH) and Johnson & Johnson (JNJ) - The Globe and Mail

Feb 04, 2026

TransMedics Group Inc (NASDAQ:TMDX): A GARP Stock with Strong Growth at a Fair Price - ChartMill

Feb 04, 2026

Up 95% In Last 12 Months, Can TransMedics Stock Keep Climbing In 2026? - TIKR.com

Feb 04, 2026

Feb 03, 2026